Clinical trial
Quetiapine Augmentation for Treatment-resistant PTSD
NCT00292370 · VA Office of Research and Development, U.S. Fed · Completed
Key facts
| NCT number | NCT00292370 |
|---|---|
| Title | Quetiapine Augmentation for Treatment-resistant PTSD |
| Official title | A Placebo-controlled Trial of Adjunctive Quetiapine for Refractory PTSD |
| Lead sponsor | VA Office of Research and Development, U.S. Fed |
| Collaborators | AstraZeneca Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Combat Disorders, Stress Disorders, Post-Traumatic |
| Intervention type | Drug |
| Interventions | Open Label (OL) Paroxetine, Placebo, Quetiapine |
| Enrollment | 124 |
| Start date | Jan 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | May 1, 2009 |
| First posted | Feb 15, 2006 |
| Last update posted | Oct 16, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: